Anemia: Not just an innocent bystander?

Archives of Internal Medicine

Volumn 163, Issue 12, 2003, Pages 1400-1404

  Nissenson, Allen R ^a   Goodnough, Lawrence T ^a   Dubois, Robert W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ACUTE HEART INFARCTION; AGING; ANEMIA; BLEEDING; BLOOD TRANSFUSION; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH EDUCATION; HEALTH SURVEY; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NOTE; NUTRITIONAL DEFICIENCY; OUTCOMES RESEARCH; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE;

AGED; ANEMIA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASMS; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE;

EID: 0037663745     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.12.1400     Document Type: Note

References (68)

1. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine, part I: blood transfusion. N Engl J Med. 1999;340:438-444.
2. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for red blood cell transfusion. Ann Intern Med. 1992;116:393-402.
3. , American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med. 1992;116:403-406.
4. DeMaeyer E, Adiels-Yagman M. The prevalence of anaemia in the world. World Health Stat Q. 1985;38:302-316.
5. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat. 1999;10 (200). Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10_200.pdf. Accessed March 4, 2003.
6. Dallman PR, Yi PR, Johnson C. Prevalence and causes of anemia in the United States, 1976 to 1980. Am J Clin Nutr. 1984;39:437-445.
7. Gordeuk VR, Brittenhamn GM, Bravo J, Hughes MA, Keating LJ. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion. 1990;30:239-245.
8. Conrad ME. The Hippocratian principle of primum nil nocere demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma: how much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency? Vox Sang. 1981;41:336-343.
9. McLennan WJ, Andrews GR, Macleod C, Caird FI. Anemia in the elderly. Q J Med. 1973;165:1-13.
10. Parsons PL, Withey JL, Kilpatrick GS. The prevalence of anemia in the elderly. Practitioner. 1965;195:656-660.
11. Joosten E, Pelemans W, Hiele M, Noyen J, Uerhaeghe R, Boogaerts MA. Prevalence and causes of anemia in a geriatric hospitalized population. Gerontology. 1992;38:111-117.
12. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ. Incidence of anemia in older people: an epidemiologic study in a well-defined population. J Am Geriatr Soc. 1997;45:825-831.
13. Siciliano M, Tomasella D, Milani A, Ricerca BM, Storti S, Rossi L. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology. 1995;22:1132-1135.
14. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum. 1990;19:209-223.
15. Zon LI, Arkin C, Groopman JE. Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol. 1988;25:208-212.
16. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
17. Ma J, Ebben J, Xia H, et al. Hematocrit levels and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610-619.
18. Collins A, Xia H, Ebben J, et al. Change in hematocrit and risk of mortality. J Am Soc Nephrol. 1998;9(suppl A):204A.
19. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465-2473.
20. Maeda K, Tanaka Y, Tsukano Y, et al. Multivariate analysis using a linear discriminate function for predicting the prognosis of congestive heart failure. Jpn Circ J. 1982;46:137-142.
21. Carson JL, Duff A, Poses RM, et al. Effect of anemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055-1060.
22. Hebert PC, Wells G, Sweeddale M, et al. Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med. 1997;155:1618-1623.
23. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13:1928-1936.
24. Silverberg OS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1776-1779.
25. Wu WC, Rathmore SS, Wang Y, Radford MJ, Krumholz HM. Effectiveness of blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230-1236.
26. Duke M, Abelman WH. The hemodynamic response to chronic anemia. Circulation. 1969;39:503-515.
27. Ogawa T, Spina RJ, Martin WH III, et al. Effects of aging, sex and physical training on cardiovascular responses to exercise. Circulation. 1992;86:494-503.
28. Levy PS, Song-Jung K, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol. 1993;265:H340-H349.
29. Maggioni AA, Meseri A, Fresco C, et al, for the Investigators of the Gruppo Italiano por lo Studio della Sopravvivenza nell'infartoo Miocardico (GISSI-2). Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med. 1993;329:1442-1448.
30. Goodnough LT, Bach RG. Anemia, transfusion, and mortality. N Engl J Med. 2001;345:1272-1273.
31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
32. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity,and mortality in end stage renal disease. Am J Kidney Dis. 1996;28:53-61.
33. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
34. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354.
35. Silverberg JS, Rahal DP, Patton R, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 1989;64:222-224.
36. Canella G, LaCanna G, Sandrini M, et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant. 1991;6:31-37.
37. Collins A, Ma JZ, Ebben J, et al. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20:345-349.
38. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis. 1999;33:1122-1130.
39. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001;38;443-464.
40. Low I, Grutzmacher P, Bergmann M, Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol. 1989;31:26-30.
41. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol. 1991;11:54-60.
42. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 1992;124:424-427.
43. Foley RN, Parfrey PS, Morgan J, et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol. 1998;9:208.
44. Linde T, Wikstrom B, Andersson LG, Danielson BG. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischemic heart disease. Scand J Urol Nephrol. 1996;30:115-120.
45. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(suppl):1A-38A.
46. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist 2000;5(suppl 2):1-7.
47. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys. 1986;12:2047-2050.
48. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536.
49. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol. 1996;14:1055-1064.
50. Fein DA, Lee WR, Hanlon L, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077-2083.
51. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42:1069-1075.
52. Moreno F, Sanz-Guaiardo D, Lopez-Gomez JM, Jofre R, Valderrabano F, for the Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol. 2000;11:335-342.
53. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
54. Demetri GD, Kris M, Wade J, Degos L, Cela D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
55. Cleveland CS, Demetri GD, Glaspy J, et al. Identifying hemoglobin level for optimal quality of life: results on an incremental analysis. Proc Am Soc Clin Oncol. 1999;18:574a.
56. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(suppl 2):S2-S8.
57. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol. 2001;19:2865-2874.
58. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
59. Nissenson AR, Collins AJ, Hurley J, Peterson H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12:1713-1720.
60. Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients. Am J Nephrol. 1990;10:213-221.
61. National Kidney Foundation. NFK-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure: National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30(4 suppl 3):S192-S240.
62. Flanigan MJ, Rocco MV, Prowant B, Frederick PR, Frankenfield DL. Clinical performance measures: the changing status of peritoneal dialysis. Kidney Int. 2001;60:2377-2384.
63. US Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: US Government Printing Office; November 2000.
64. Consensus conference: perioperative red blood transfusion. JAMA. 1988;260:2700-2703.
65. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732-747.
66. Expert Working Group. Guidelines for red blood cell and plasma transfusions for adults and children. CMAJ. 1997;156(suppl 11):S1-S25.
67. O'Brien MM, Gonzales R, Shroyer AL, et al. Modest serum creatinine elevation affects adverse outcome after general surgery. Kidney Int. 2002;62:585-592.
68. Transfusion Medicine/Hemostasis Clinical Research Network. Available at: http://grants.nih.gov/grants/guide/rfa-files/rfa-HL-02-001.html. Accessed March 4, 2003.